Bayer Signs a License and Research Agreement with Gubra to Develop Novel Peptide Therapeutics for Cardiorenal Diseases

 Bayer Signs a License and Research Agreement with Gubra to Develop Novel Peptide Therapeutics for Cardiorenal Diseases

Bayer Signs a License and Research Agreement with Gubra to Develop Novel Peptide Therapeutics for Cardiorenal Diseases

Shots:

  • Gubra to receive ~ $253.4M as up front, development, and commercialization milestones
  • The collaboration will combine Gubra’s peptide drug discovery capabilities with Bayer’s expertise to develop innovative medicines to treat cardiorenal diseases
  • The collaboration also use Gubra’s streaMLine which is an ML based peptide drug discovery platform & is used for fast screening and identification of potent therapeutic peptide candidates

Click here to­ read full press release/ article | Ref: Gubra | Image: Crunchbase

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post